Disc Medicine reports tomorrow with short conviction at its highest point in recent weeks — and the options market quietly shifting in the same direction.
The dominant positioning story remains short interest, which has continued to build since the last article published on June 10. Bears now hold 15.6% of the free float — 5.9 million shares — up nearly 7% on the week and 17% over the past month. The ORTEX short score reached 74.6 on June 15, a fresh high for the recent run, with the score rising in six of the last ten sessions. Options positioning has also edged more defensive into the print: the put/call ratio climbed to 0.20, running above its 20-day average and roughly 1.3 standard deviations elevated — modest in absolute terms, but the direction of travel matters. One contrast worth naming: the borrow market remains loose. Availability runs at 239%, meaning there are more than two shares available to borrow for every one already shorted. Cost to borrow has ticked up 9% on the week but is still only 0.61% — not the signature of a stressed lending market. The short-side pressure is a positioning choice, not a supply squeeze.
The bull-bear divide is sharpest on the question of bitopertin's clinical profile. Bulls point to a credible pipeline across erythropoietic porphyria, anemia of myelofibrosis, and chronic kidney disease, with sum-of-parts analysis underpinning targets that remain well above the current $69.83 price. Morgan Stanley raised its target to $85 yesterday — the second increase from that firm since mid-May — while Wedbush reiterated an $88 Outperform last week. The mean analyst target sits near $102, implying roughly 45% upside from here, though most targets were reset lower in February after disappointing clinical data and reflect a rebuilding rather than a conviction consensus. Bears focus precisely on that February reset: hematologic response rates in key trials fell short of expectations, and the company has yet to demonstrate the regulatory clarity needed to move bitopertin toward commercialization. The clinical-stage discount is real.
Institutional ownership adds one layer of context. FMR added 586,000 shares in the most recent reported period, lifting its stake to 14.6% — the largest holder by a wide margin. State Street added 510,000 shares and RA Capital added 474,000. The buying from active specialist managers like RA Capital and BVF Partners, which added 622,000 shares, suggests the bull case retains serious institutional backing. Insider activity has been exclusively sales — the CFO, CMO, and COO all sold in April and February — but the volumes are modest and likely reflect routine compensation-related disposals rather than a directional view.
Tomorrow's print will test whether Disc Medicine can offer enough pipeline progress — particularly any update on the FDA pathway for bitopertin — to justify a stock trading at 6.5x book with no near-term earnings and a short base that has been methodically rebuilt over the past six weeks.
See the live data behind this article on ORTEX.
Open IRON on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
